What is Biophytis S.A. (BPTS)?

Biophytis S.A. (BPTS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BPTS?

The current price of BPTS is $8.22. Prices are updated in real time on Stocks360.

What is BPTS's price-to-earnings (PE) ratio?

BPTS's trailing twelve-month PE ratio is -0.58, based on current price and earnings per share data available on Stocks360.

What is BPTS's market capitalization?

BPTS's market capitalization is $2,608,625.00, placing it in the small-cap tier.

Biophytis S.A. (BPTS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$8.22

Market Cap

$2.61M

PE (TTM)

-0.58

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.05

Day Range

$8.05 – $8.96

52-wk Range

$8.05 – $168.80

Avg Volume

N/A

Volume

17.95K

Biophytis S.A. (BPTS) is a publicly traded company in the Healthcare sector. Latest price: $8.22. Market cap $2.61M. Trailing PE -0.58. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Apr 8, 2024

EPS $-5.37 vs est. $-0.30

Missed by $5.07

Proprietary Signals

Signal snapshot temporarily unavailable.

About Biophytis S.A.

Biophytis S.A. operates as a clinical-stage biotechnology firm dedicated to advancing therapeutic solutions aimed at decelerating degenerative processes and enhancing functional outcomes for individuals grappling with age-related illnesses. These therapies function by targeting and stimulating critical biological resilience pathways, which are designed to offer protection against and counteract the detrimental effects of various biological and environmental stressors contributing to age-associated pathologies. The company's flagship pharmaceutical candidate is Sarconeos (BIO101), an orally administered small molecule currently under development for addressing a spectrum of neuromuscular conditions, notably sarcopenia and Duchenne muscular dystrophy (DMD). Additionally, it is progressing through a Phase 2/3 clinical study to treat severe respiratory compromise in patients afflicted with COVID-19. Biophytis is also developing Macuneos (BIO201), another oral small molecule intended for ophthalmic disorders such as dry age-related macular degeneration (AMD) and Stargardt disease. In a collaborative effort, Biophytis SA has partnered with AFM-Telethon specifically for the advancement o…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.58×
P/S (TTM)	0.00×
P/B	-2.58×
P/FCF (TTM)	-0.18×
EV / EBITDA	-0.37×
EV / Sales	0.00×
Earnings Yield	-170.93%
Free Cash Flow Yield	-562.05%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$5.03M
Net Income (TTM)	-$3.98M
Free Cash Flow (TTM)	-$11.95M
Net Debt	$2.70M
Working Capital	-$3.52M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	593.65%
Return on Invested Capital	-285.79%